Astellas- Drug ASP546C for CLDN18.2-expressing solid tumors (546C-CL-0201)

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
[546C-CL-0201] A Phase 1b/2 Open-label Study to Assess the Safety and Efficacy of ASP546C in Participants with CLDN18.2-expressing Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma, Pancreatic Adenocarcinoma or Other Solid Tumor Types
Principal Investigator
Headshot of John Strickler
Professor of Medicine
Protocol Number
IRB: PRO00119707
NCT: NCT07488676
Phase
Phase I/II
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL